



Michael K Gibson, MD, PhD, FACP, is Co-Leader of the Esophageal Cancer Program and Assistant Professor of Medicine and Cardiothoracic Surgery at the University of Pittsburgh Cancer Institute (UPCI). His research focuses on translating novel therapeutics for treatment of upper gastrointestinal (UGI) cancers. To forward this effort, he leads the multidisciplinary UGI clinical trials program at the UPCI and co-leads the translational laboratory effort in esophageal cancer. Dr Gibson is Principal Investigator on multiple clinical trials supported by industry, investigator-initiated mechanisms and the National Cancer Institute (NCI) cooperative groups. He is a member of the NCI Esophago-Gastric Task Force, the Eastern Cooperative Oncology Group Gastrointestinal Committee, and the NCI Central Institutional Review Board. Dr Gibson has authored articles in multiple journals, including the *Journal of Clinical Oncology* and *Clinical Cancer Research*. He has presented his research at numerous meetings, including those of the American Society of Clinical Oncology, the World Organization for Specialized Studies on Diseases of the Esophagus, and the Japan Esophageal Society.

This issue of *Oncology & Hematology Review* presents a variety of topics sure to be of practical use to our readers. We are pleased to offer a range of subjects that are relevant to the practice of hematology and oncology. To start, one will find an update of medical ethics in the setting of gynecologic oncology. The issue continues with a series of articles and reviews regarding a breadth of solid tumors, then closes with hematologic malignancies and pediatric oncology.

Ethics is of particular concern to practicing oncologists and hematologists. Recent topics on the forefront include: allocation of limited and/or expensive resources, death and dying in the era of increasingly sophisticated life-sustaining technology, and skills needed to interact with families and patients during times of great stress. Beyond the basic principles of beneficence, autonomy, and justice lies the more nuanced application of these ideals in the setting of patient-specific situations. Professor Gallagher illustrates this with a case.

Regarding the treatment of solid tumors, several themes predominate, including multimodality care of gastrointestinal (GI) malignancies and soft tissue cancers, and molecular as well as focused radiotherapy for gynaecological, GI, and breast cancers. In particular, these last two approaches aim to both increase efficacy and reduce toxicity by minimizing bystander effect. Multimodality approaches, ubiquitous in solid tumor oncology, aim to maximize both loco-regional and systemic control.

Roberge and Pocinho present their experience with targeted radiotherapy, otherwise known as stereotactic body radiation. Their goal is to eliminate colorectal cancer liver metastases non-invasively. Additional approaches are outlined for basal-like breast, cervical and vaginal cancers.

Several updates on multimodality care for GI malignancies are also presented. Fernández-Martos and colleagues evaluate the use of induction chemotherapy in advance of chemoradiotherapy (CRT) for rectal cancer. For retroperitoneal soft tissue sarcoma, Gronchi and colleagues report their experience with pre-operative CRT.

Two articles about hematologic malignancies follow. Flowers and colleagues tie together the complicated and diverse spectrum of diffuse large B-cell lymphoma. Following this, Porrata et al. review the advantages and pitfalls of the complete blood count in prognosis. Completing this issue is a discussion of sleep concerns in the setting of pediatric sickle cell disease.

Oncology & Hematology Review is pleased to offer you this issue. We are grateful to the authors, editors, and staff who worked to create such an outstanding offering. In addition, we wish to thank all organizations and media partners for their ongoing support. The Editorial Board is also thanked for its continued involvement. Enjoy and learn from our journal! ■



Save the Date

MASCC/ISOO

INTERNATIONAL SYMPOSIUM ON SUPPORTIVE CARE IN CANCER

New York City, June 28-30, 2012

Supportive Care Makes Excellent Cancer Care Possible

The Multinational Association of Supportive Care in Cancer (MASCC) is a global, multidisciplinary organization, dedicated to education and research of supportive care for people with cancer at all stages of their disease. Visit our website at www.mascc.org.

MASCC/ISOO 2012 - The Cancer Care Symposium

The annual symposium focuses on the clinical management of supportive care in oncology. It is essential that all oncology specialists, care-givers and cancer policy makers are fully updated as to the latest available physical and psychological treatments to prevent, control, or relieve complications and side effects of cancer and its treatments — including antineoplastic approaches. This advanced scientific oncology congress is endorsed by the leading Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology.

Let's meet in the exhilarating city of New York to combine our efforts and knowledge to explore how we can all improve patient's comfort and quality of life!

Register today: <http://www.kenes.com/mascc>

Symposium Topics

- Bone Metastases
- Cachexia
- Cancer Pain
- Cutaneous Toxicity
- Dyspnea
- Education in Supportive Care
- End-Stage Disease
- Fatigue
- Hematologic Toxicity
- Lymphedema
- Mucositis
- Nausea-Vomiting
- Neurological Complications
- Neutropenia-Infections
- Nutrition
- Oral Complications
- Paediatrics
- Palliative Care
- Psychooncology
- Thromboembolic Events
- Quality of Life
- Rehabilitation
- Survivorship
- Treatment of Specific Toxicities
- Other Supportive Care